This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Veterinary medicines European public assessment report (EPAR): Elmaro, maropitan...
Veterinary medicines European public assessment report (EPAR): Vectormune HVT-AI...
Summary of opinion: Porcilis ColiClos, 12/02/2025 Positive
Human medicines European public assessment report (EPAR): Opfolda, miglustat, Da...
Human medicines European public assessment report (EPAR): Lyumjev (previously Li...
Product Management Service (PMS) webinar : Unlocking Integration – MAH & Softwar...
Article 57 product data
Guideline on assessment and reporting of mechanistic models used in the context ...
Human medicines European public assessment report (EPAR): Dupixent, dupilumab, D...
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, D...
Human medicines European public assessment report (EPAR): Ambrisentan Viatris (p...
Guideline on 5 assessment and reporting of mechanistic models used in 6 the cont...
QRD veterinary product-information template version 9.1
QRD veterinary product-information highlighted template version 9.1
Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: han...
Human medicines European public assessment report (EPAR): Bortezomib Fresenius K...
Human medicines European public assessment report (EPAR): Tabrecta, capmatinib, ...
Human medicines European public assessment report (EPAR): Docetaxel Accord, doce...
Opinion/decision on a Paediatric investigation plan (PIP): Ervebo, Ebola Zaire V...